Arvinas, Novartis to Develop, Commercialize Protein Degrader to Treat Prostate Cancer

 

• Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 billion in development, regulatory, and commercial milestones, as well as tiered royalties
• Novartis to be responsible for worldwide clinical development and commercialization of ARV-766
• Partnership expected to accelerate and broaden the development of ARV-766 as a potential first-in-class treatment option for patients with prostate cancer

https://www.biospace.com/article/releases/arvinas-enters-into-a-transaction-with-novartis-including-a-global-license-agreement-for-the-development-and-commercialization-of-protac-androgen-receptor-ar-protein-degrader-arv-766-for-the-treatment-of-prostate-cancer/